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Bozepinib: A Promising Selective 
Derivative Targeting Breast Cancer 
Stem Cells
Joaquín M. Campos, Ana Conejo-García 
and Olga Cruz-López
Abstract
Bozepinib is a potent antitumour compound that shows an IC50 of 0.166 μM 
against MDA-MB-231 human breast cancer cell line. It is also a very selective drug 
that presents a therapeutic index (TI) of 11.0 against MDA-MB-231 in relation to 
the normal MCF-10A. It is important to identify new cancer stem-like cells (CSCs) 
anticancer drugs to struggle against the resistance and the high risk of relapse in 
patients. In the present chapter, we show how bozepinib demonstrated selectivity 
on cancer cells and showed an inhibitory effect over kinases involved in carcinogen-
esis, proliferation and angiogenesis. Bozepinib inhibits HER-2 signaling pathway 
and JNK and ERK kinases. In addition, it has an inhibitory effect on AKT and VEGF 
together with anti-angiogenic and anti-migratory activities. Interestingly, bozepinib 
suppresses the formation of both mammo- and colonospheres and eliminated 
ALDH+ CSC subpopulations at a low micromolar range similar to salinomycin. It 
also induces the downregulation of SOX2, c-MYC and β-CATENIN and upregula-
tion of the GLI-3 Hedgehog signaling repressor. Finally, bozepinib shows in vivo 
antitumor and anti-metastatic efficacy in xenotransplanted nude mice without 
presenting subacute toxicity. However, further studies in cancer patients are needed 
to confirm the therapeutic potential of bozepinib.
Keywords: benzoxazepine, bozepinib, cancer stem-like cells, MDA-MB-231, MCF-7, 
MCF-10A, protein kinases, seven-membered ring
1. Introduction
Expansion of cancer keeps going on as an important health problem in the 
developed, undeveloped and developing countries. Although major advances have 
been made in the chemotherapeutic management of some patients, the continued 
commitment to the laborious task of discovering new anticancer agents remains 
critically important, in the course of identifying various chemical substances, 
which may serve as leads for designing novel antitumor agents.
1.1 Cancer stem cells
Currently, one of the most interesting concepts being explored in can-
cer research is the theory of cancer stem cells. CSCs can be defined as the 
Translational Research in Cancer
2
subpopulations of cells within tumors that possess the ability to self-renew and 
differentiate into the different lines of cancer cells that make up the tumor. This 
type of cell is proposed as the promoter of resistance against antitumor therapies, 
being able to maintain benign and malignant tumors, as well as causing relapses [1]. 
Compared to normal stem cells, CSCs are thought to have no control over their 
proliferation. These CSCs, present in tumors in small numbers, are characterized by 
their ability to remain quiescent for long periods of time, capacity for self-renewal, 
maintenance of growth and heterogeneity of the tumor, affinity for environment 
resistance to chemotherapy and development of metastases [2].
CSCs are characterized by their ability to form spherical colonies when culti-
vated in suspension [3]. Al-Hajj et al. managed to demonstrate that the injection of 
200 tumoural cells expressing characteristic markers of CSCs was more effective in 
generating tumors in immunodepressed mice than the injection of 50,000 tumor 
cells with differentiated cell markers of the same histological lineage [4]. It has been 
found that multiple molecules related to the characteristic properties of stem cells 
such as self-renewal and pluripotency and certain enzymatic activities are largely 
expressed in CSCs, including c-MYC, β-CATENIN [5], SOX-2 [6] and aldehyde 
dehydrogenase activity (ALDH1) [7]. New strategies for selective and effective 
cancer therapy can be provided by selectively acting on overregulated pathways 
or molecules in differentiated cancer cells and/or in CSC populations, but not in 
normal cells.
1.2 Therapies targeted against cancer stem cells
Cancer treatment currently targets its proliferation potential, and therefore 
most treatments target rapidly dividing cells. The presence of CSCs may explain 
the failure of treatments to eradicate the disease or the recurrence of cancer [1]. 
CSCs have to remain in a state of quiescence, a state in which the cell does not divide 
staying in the G0 phase of the cell cycle [8] allows them to survive most anticancer 
treatments. This characteristic makes relapses possible, even decades after initial 
treatment, such as in colon or breast cancers [1, 9]. Although current treatments 
may reduce the tumor size, these effects are transient and generally do not improve 
patients’ survival. For tumors in which CSCs play a role, there are three possibili-
ties. First, the mutation of normal stem cells or CSC progenitor cells can lead to the 
development of the primary tumor. Second, during chemotherapy, most cells in 
the primary tumor can be destroyed, but if CSCs are not eradicated, they become 
refractory CSCs and can lead to the recurrence of the tumor [10]. Third, CSCs 
can migrate to distant sites of the primary tumor and cause metastasis [11–13]. 
Theoretically, the identification of CSCs can allow the development of treatment 
modalities that target these cells rather than rapidly dividing cells [14].
One of the therapeutic approaches currently being studied to combat CSCs is 
related to the signaling pathways involved in the processes of their self-renewal, 
proliferation and differentiation. This is because the loss of regulation of pathways 
such as Hedgehog (Hh), Notch and Wnt/β-catenin results in the key processes 
involved in the characteristics of CSCs. Currently, the therapy directed against 
these routes represents one of the most promising mechanisms of action against 
these initiation cells of the tumor [15, 16].
Herein we will discuss the search and biological activity of small synthetic 
derivatives: racemate 2, named as bozepinib (isomer of 1), was selected for anti-
CSC studies (Figure 1). The information presented in this chapter should be of 
interest to medicinal chemists and represents an effort to summarize the experi-
mental research and advances in the field of CSCs [17, 18].
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A better understanding of the molecular mechanisms responsible for CSC 
formation probably lead to the design and synthesis of new anticancer drugs which 
will be able to eliminate CSC or to halt tumor growth by interfering with important 
intracellular signaling pathways related with CSC stemness or CSC differentiation 
or both.
2.  (RS)-2,6-Dichloro-9-[1-(o- or p-nitrobenzenesulfonyl)-1,2,3,5-
tetrahydro-4,1-benzoxazepine-3-yl]-9H-purines 1 and 2
2.1  Synthesis of tetrahydrobenzoxazepine O,O-acetals with electron 
withdrawing groups on the nitrogen atom
As part of an Anticancer Drug Programme, we were interested in the prepara-
tion of the heterocycles 3a-b (Figure 2) that could be useful intermediates for the 
synthesis of novel bioactive compounds. Figure 2 shows the synthesis of derivatives 
3a-b [19]. The Mitsunobu reaction is a versatile method for the transformation of 
aliphatic alcohols into alkylating agents in situ and under mild conditions [20]. A 
successful Mitsunobu displacement depends on the pKa associated with the N▬H 
bond [21]. Thus, a powerful electron withdrawing group for the amino moiety was 
needed such as the p- or o-nitrobenzenesulfonyl fragment.
The synthesis of compounds 3a-b begins with the protection of the hydroxyl 
group of anthranilic alcohol by the tert-butyldimethylsilanyl group to give 4; the 
synthesis of sulfonamides 5a and 5b was accomplished under the conditions of 
Fukuyama et al. [22]. Compound 6a was obtained in a 70% yield under Mitsunobu 
conditions from 5a and glycolaldehyde dimethyl acetal. The yield of this reaction 
depends greatly on the temperature: at rt., it is 19%, increasing up to 70% at 30°C 
and falling to 40% when the temperature is 40°C (Figure 2). When the optimized 
temperature conditions were applied to 5b, 6b was obtained in an 80% yield. After 
deprotection of the silanyl group of 6a (and 6b) with tetra-n-butylammonium 
fluoride (TBAF) in tetrahydrofuran (THF), 7a was obtained in an 83% yield (and 
7b in 100% yield). Compounds 7a and 7b quantitatively afforded the benzo-fused 
seven-membered O,O-acetals 3a and 3b, respectively, using boron trifluoride 
diethyl etherate as previously reported [23].
Figure 1. 
Chemical structures of bezoxazepine derivatives 1 and 2.
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Until compounds 3a and 3b were obtained under the optimal conditions 
described above, other conditions were studied giving rise to unwanted products. 
Product 5b was obtained using a twofold excess of the o-aminobenzyl silanyl ether 
4, and these conditions were most important for the preparation of this compound 
(5b, Figure 2). Actually, the derivative 8 was isolated when the reaction was carried 
out using triethylamine (TEA) as a hydrochloride acid scavenger and 1.1 equiv. of 
the sulfonyl chloride was added (Figure 3) [19].
A reasonable explanation implied the previous ionization of the sulfonamide 
hydrogen atom of 5b to give a −NSO2 anion which reacts more rapidly than the 
starting amine to give 8. Disulfonimides have been stated [24] to be by-products in 
reactions of sulfonyl halides with primary amines and ammonia. The o-nitro group 
might sterically hinder the −NSO2 anion, and therefore the analogous side product 
was not isolated.
We also investigated other conditions to synthesize 6b (Figure 4) [19]. The 
isopropyl alkylated derivative 9 (38%) was obtained together with the expected 
acetal 6b (31%) when an excess of glycolaldehyde dimethyl acetal (4.3 equiv) was 
added. Such a compound could be interpreted by the transesterification reaction of 
glycolaldehyde dimethyl acetal and diisopropyl azodicarboxylate (DIAD), with the 
concomitant leaving of isopropanol. A similar process was previously reported for 
diethyl azodicarboxylate (DEAD) but not when DIAD was used [25].
The O,O-acetals 3a and 3b were formed after treatment of the p-toluenesulfonic 
acid-mediated cyclization from the acyclic acetals 7a and 7b, using anhydrous 
Figure 2. 
Reagents and conditions: (a) o-O2N-C6H4-SO2Cl (1.1 equiv), TEA (1.5 equiv), CH2Cl2, reflux, 24 h, for 
5a; p-O2N-C6H4-SO2Cl (0.5 equiv), CH2Cl2, rt., 3 h, for 5b; (b) HOCH2CH(OMe)2 (1 equiv), diisopropyl 
azodicarboxylate (DIAD, 1.1 equiv), PPh3 (1.2 equiv), anhydrous THF, 21 h; (c) TBAF (1 equiv), THF, rt., 1 h; 
(d) BF3·OEt2 (2 equiv), anhydrous Et2O, rt., 7 days for 3a; when these conditions were used to obtain 3b, the 
yield was 67%; p-H3C-C6H4-SO3H (0.03 equiv), anhydrous toluene, 110°C, 2 h under argon for 3a and 3b [19].
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toluene as solvent. When neutral and mild conditions using triphenylphosphine/
carbon tetrachloride were employed, the substitution of the hydroxyl group by 
the chlorine took place, and compounds 10a and 10b were obtained instead of the 
cyclic derivatives 7a and 7b (Figure 5) [26]. Compounds 7a and 7b present bulky 
groups that limit their conformational motions, making them rigid structures. The 
oxygen atoms of the acetalic groups cannot act as nucleophiles against the benzylic 
position (with the triphenylphosphine ether) due to steric hindering. Hydrogen 
atoms of the methylene groups of both compounds (7a and 7b) are diastereotopic 
protons (Jgem = 12.6–14.1 Hz) [19].
Figure 3. 
Reagents and conditions: (a) p-O2N-C6H4-SO2Cl (1.1 equiv), TEA (1.5 equiv) and anhydrous CH2Cl2, rt., 5 h 
when 0.5 equiv. of p-O2N-C6H4-SO2Cl was used, see Figure 2 (conversion 4 → 5b) [19].
Figure 4. 
Reagents and conditions: (a) HOCH2CH(OMe)2 (4.3 equiv), DIAD (1.2 equiv), PPh3 (1.2 equiv) and 
anhydrous THF, rt., 18; h; when 1.2 equiv. of HOCH2CH(OMe)2 were used, see Figure 2 (conversion 
5b → 6b) [19].
Figure 5. 
Reagents and conditions: (a) Ph3P (1 equiv), CCl4, 110°C, 30 min [19].
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2.2  Synthesis of tetrahydrobenzoxazepine 2,6-dichloropurine O,N-acetals with 
nitrosulfonyl groups on the nitrogen atom
The preparation of the O,N-acetals 1 and 2 was achieved by the microwave-
assisted Vorbrüggen one-pot condensation of the cyclic acetals 3a and 3b [27] and 
the commercially available purine base 2,6-dichloropurine, using trimethylsilyl 
chloride (TMSCl), 1,1,1,3,3,3-hexamethyldisilazane (HMDS) and tin(IV) chloride 
as the Lewis acid in anhydrous acetonitrile. The reaction mixture was microwave-
irradiated at a temperature of 140°C for 5 min (Figure 6).
Compounds 11 and 12 were obtained along with the cyclic 2,6-dichloropurine 
O,N-acetals (1 and 2, bozepinib) and the acyclic one 13 (when starting from 3b) in 
the reaction of purines with 3a and 3b, respectively. The mechanism of the reaction 
of these compounds is important as none of them were previously isolated in the 
Figure 6. 
Reagents and conditions: (a) 3a (1 equiv), 2,6-dichloropurine (1.5 equiv), trimethylsilyl chloride (TMSCl, 1.5 
equiv), 1,1,1,3,3,3-hexamethyldisilazane (HMDS, 1.5 equiv) and SnCl4 (1 M solution in CH2Cl2, 1.5 equiv), 
140°C, microwave, 5 min; (b) 3b (1 equiv), 2,6-dichloropurine (2.5 equiv), TMSCl (4.0 equiv), HMDS (4.0 
equiv) and SnCl4 (1 M solution in CH2Cl2, 4.0 equiv), 140°C, microwave, 5 min.
7Bozepinib: A Promising Selective Derivative Targeting Breast Cancer Stem Cells
DOI: http://dx.doi.org/10.5772/intechopen.91423
corresponding reactions with uracil or 5-FU [27]. We have previously explained the 
mechanism of the reaction leading to the benzo-fused derivatives 1, 2, 11 and 12 [28].
2.3 Homochiral drugs
A better understanding of the molecular recognition of the therapeutic targets 
in many diseases highlights the issue of drug in the design and development of new 
drugs. The separation of racemates, chiral pool and asymmetric synthesis are the 
three most used methods for the production of a chiral drug. Since the 1980s there 
has been a significant increase in the development of chiral pharmaceutical drugs. 
When patents of racemic drugs expire, pharmaceutical companies can extend 
patents by developing the synthesis of enantiomers that exhibit the desired biologi-
cal activity [29].
Compound 2 was resolved into its two enantiomers: [(R)-2: [α]25D = −43.6 
(c = 0.22, THF) and (S)-2: [α]25D = +41.0 (c = 0.23, THF)]; using a semipreparative 
column CHIRALPAK® and a mixture of hexane/t-BuOMe/iPrOH as eluant [28]. 
From this moment on, the racemic 2 [(RS)-2] will be named only as bozepinib.
2.4 Biological studies
Table 1 shows the anti-proliferative activity (IC50 values) for 1, bozepinib and 
5-fluorouracil (5-FU) as a reference drug. Compounds were first assayed as anti-
proliferative agents against the human breast adenocarcinoma cell line MCF-7 (p53 
wild type and ras mutated). Compounds 1 and bozepinib were further assayed 
against the human breast cancer cell line MDA-MB-231 which presents high levels 
of mutant p53 [28, 30]. The IC50 = 0.166 μM for bozepinib against the human 
cancerous cell line MDA-MB-231 stands out.
In order to determine the in vitro therapeutic index of the compounds, they 
were assayed against the non-cancerous human mammary epithelial cell line MCF-
1oA. The TI of a drug is defined as the ratio of the toxic dose to the therapeutic dose 
(in vitro TI = IC50 non-tumor cell line/IC50 tumor cell line) [28]. Bozepinib is more 
selective against both human breast adenocarcinoma MCF-7 and MDA-MB-231 
cancer cell lines (TIs = 5.14 and 11.0, respectively) in relation to the normal one 
(Table 2).
As bozepinib is more active and more selective and more active than its iso-
mer 1, we decided to carry out the separation of bozepinib into their component 
enantiomers (resolution). (S)-2 shows higher anti-proliferative effect that of 
(R)-2 in the MCF-7 cell line. However no differences against the MDA-MB-231 cell 
line were observed (Table 3). The enantioselective cytotoxicity indicates that the 
Compound IC50 MCF-7 (μM) IC50 MDA-MB-231 (μM) IC50 MCF-10A(μM)
1 0.383 ± 0.027 0.280 ± 0.006 1.530 ± 0.198
Bozepinib 0.355 ± 0.011 0.166 ± 0.063 1.825 ± 0.503
5-FUc 4.32 ± 0.020 N.D.b N.D.b
aAll experiments were conducted in duplicate and gave similar results. Data are means ± SEM of three independent 
determinations. The treatment time was 48 h.
bN.D. = not determined.
cTaken from Ref. [31].
Table 1. 
Anti-proliferative activitiesa for compounds 1 and bozepinib against the cancerous cell lines MCF-7 and 
MDA-MB-231 and the non-cancerous cell line MCF-10A.
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enantiomers of some chiral drugs may differ both quantitatively and qualitatively in 
their biological activity [32, 33]. Moreover, enantiomers can show minimal in vitro 
but a dramatic in vivo chiral dependency in their antitumor activities [34, 35].
2.4.1 Effect of bozepinib against CSC subpopulations
The cytotoxic effect of bozepinib was determined on SKBR-3 and MDA-MB 468 
breast and HCT-116 colon CSC-enriched subpopulations by growing them into low 
attachment plates with sphere-forming medium for 72 h. Salinomycin is a selective 
and potent drug used in the treatment of CSCs, but its use is limited in humans due 
to considerable toxicity [36]. Thus, we decided to include salinomycin in our studies 
as reference drug. Bozepinib displayed IC50 values in a similar range to salinomycin 
in SKBR-3 and MDA-MB 468 cells [30].
CSCs were separated using ALDH activity by FACS. IC50 values were determined 
in both ALDH positive cells (called ALDH+), ALDH negative cells (called ALDH−) 
and cells growing in sphere-forming medium without sorter enrichment process 
[30]. Since there is controversy about the efficacy of sphere-forming cultures to 
select CSCs [37, 38], we used ALDH activity to enrich cell cultures with clonal 
ability and stem-like properties. Bozepinib substantially diminished the number 
and size of spheres at 5 μM and abolished the formation of spheres at 20 μM [30] in 
subpopulations isolated by ALDH activity. High ALDH activity is associated with 
metastasis, resistance to chemotherapies and poor prognosis in human cancers, and 
it has been identified as one of the most specific markers of human CSCs [39].
Apoptosis is also an important factor in the onset of a tumor. It has been 
reported than CSCs are resistant to apoptosis to ensure succeeding generation [40] 
and may be on the causes to chemo- or radiotherapy survival. Reactivating death 
programmes in CSCs may increase efficacy of the treatment. Bozepinib induced a 
significant level of cell death by apoptosis in the resistant ALDH+ subpopulations 
from both SKBR-3 and HCT-116 cell lines. Higher levels of apoptosis were detected 
in the ALDH− subpopulations.
Bozepinib induced the downregulation of important genes involved in 
Notch and Wnt signaling. These genes contribute to the CSC phenotype when 
they are deregulated [41]. A downregulation was detected of the co-activator 
Compound MCF-7 (μM)a MDA-MB-231 (μM)a
Bozepinib 0.355 ± 0.011 0.166 ± 0.063
(R)-2 0.19 ± 0.001 0.11 ± 0.001
(S)-2 0.10 ± 0.001 0.11 ± 0.001
aAll experiments were conducted in duplicate and gave similar results. The data are means ± SEM of three independent 
determinations.
Table 3. 
Anti-proliferative activities of bozepinib and its enantiomers against the cancerous cell lines MCF-7 and 
MDA-MB-231.
Compound Therapeutic index (TI)
MCF-7 MDA-MB-231
1 4.00 5.50
Bozepinib 5.14 11.0
Table 2. 
Therapeutic indexes for 1 and bozepinib.
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Mastermind-like MAML-2 protein, which decreases Notch signaling, reducing the 
primary tumor sphere formation and side population in MCF-7 cell line, contribut-
ing to the decrease in the number of CSC subpopulations [42]. We also found an 
evident downregulation of the NOTCH 3 gene, which has recently been involved in 
the proliferation of both HER2 positive and negative breast cancer cells, suggesting 
that targeted suppression of this signaling pathway may be a promising strategy for 
the treatment of determined HER2-related breast cancers [43, 44].
The modification of proteins related to the CSC phenotype such as β-catenin, 
GLI-3, c-MYC and SOX-2 was additionally analysed. This study was carried out in 
both ALDH+ and ALDH− SKBR-3 breast and HCT-116 colon cancer subpopulations.
β-Catenin is a key mediator of the Wnt signaling which has a crucial role in CSCs 
[45]. β-Catenin expression was detected in ALDH+ SKBR-3 but not in ALDH− 
SKBR-3 cells. A high level of expression in HCT-116 cell lines with an ALDH+ sub-
populations in comparison with the ALDH− in HCT-116 subpopulations was also 
detected. After bozepinib treatment, β-catenin expression was reduced in ALDH+ 
HCT-116 subpopulation. Its inhibition in ALDH− HCT-116 cells was also observed.
GLI-3, a described target gene transcription repressor of Hedgehog signaling 
pathway [16], was detected in ALDH− HCT-116 isolated cells and was not present 
in the ALDH+ cells, denoting that the Hedgehog signaling pathway is involved 
in the CSC phenotype as previously reported [16]. Bozepinib greatly induced the 
expression of GLI-3 in both ALDH+ and ALDH− HCT-116 cells. However, no 
changes at protein level were observed in ALDH+/− subpopulations isolated from 
the SKBR-3 cell line. Furthermore, the activation of GLI-3 protein corresponded 
with an inactivation of β-catenin expression in CSC subpopulations after bozepinib 
treatment in accordance with the previous published studies [46]. Considering that 
GLI-3 overexpression decreased tumor cell proliferation and induced apoptosis in 
colon CSCs [47], the GLI-3 induction by bozepinib could be one of the mechanisms 
by which this drug exerts its antitumor activity in colon CSCs. This hypothesis will 
be deeply study the future.
The c-MYC oncoprotein was observed in SKBR-3 and HCT-116 cell lines with a 
high level of expression in ALDH+ subpopulations in comparison with the ALDH− 
subpopulations. Bozepinib induced a significant decrease of c-MYC level in ALDH+ 
HCT-116 cells and inhibited its expression in ALDH+ SKBR-3-treated cells. It also 
inhibited ALDH− subpopulations of both HCT-116 and SKBR-3 cells [30]. In 
accordance with the high level of stem signaling proteins described for CSCs, higher 
levels of these proteins in the ALDH+ subpopulations in comparison with ALDH-
cells were detected. The downregulation of c-MYC activates the inhibition of cancer 
cell proliferation, invasion and migration [48].
The transcription factor SOX2 was detected in HCT-116 ALDH+ subpopulation. 
However SOX2 was not observed in breast cancer cells, and the expression of SOX2 
was very weak in HCT-116 ALDH− subpopulation [30]. Its expression practically 
disappeared after treatment with bozepinib. SOX2 is involved in the induction and 
maintenance of pluripotent stem cells and has also been associated with metastases 
and poor prognosis in colon cancer [49].
2.4.2 In vivo studies of bozepinib
The acute toxicity profile of bozepinib was determined in BALB/c mice. After 
2 weeks, bozepinib was nontoxic to BALB/c mice even at the highest intraperitoneal 
bolus dose of 200 mg/kg and orally bolus dose of 50 mg/kg. Control mice were 
treated with vehicle alone. All 50 bozepinib-treated mice remained healthy and 
gained weight throughout the 15-day observation period, with no evidence of 
morbidity [28].
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We then evaluated the subacute toxicity after 29 days of intraperitoneal treat-
ment with 100 mg/kg twice a week. Bozepinib-treated mice presented no weight 
loss or unusual behaviour, and the histopathologic examination did not find any 
detectable toxicity in the liver or kidneys. These data indicate that, at the concentra-
tion used, bozepinib did not cause any systemic damage [30].
3. Conclusion
Although we show promising data proving the efficacy of bozepinib over CSCs, 
the mechanism by which bozepinib inhibits the CSC growth requires further 
detailed investigation. Moreover, the in vivo antitumor and anti-metastatic effect 
and the non-systemic toxicity of bozepinib encourage further studies on the thera-
peutic potential of this synthetic compound in breast and colon cancer patients.
The detection of CSCs in multiple solid tumors over the past years represents 
a paradigm shift in oncology and will probably change our understanding of the 
tumourigenic process. The impressive number of publications that have appeared in 
this field in recent years bears testimony to its enormous current interest.
We expect this chapter to stimulate fresh activity within the medicinal chem-
istry community and to result in the enlargement of chemical structures active 
against CSCs.
Abbreviations
ALDH aldehyde dehydrogenase activity
CSCs cancer stem cells
DEAD diethyl azodicarboxylate
DIAD diisopropyl azodicarboxylate
FACS fluorescence-activated cell sorter
5-FU 5-fluorouracil
Hh Hedgehog
HMDS 1,1,1,3,3,3-hexamethyldisilazane
PKR protein kinase R
TBAF tetra-n-butylammonium fluoride
TEA triethylamine
THF tetrahydrofuran
TI therapeutic index
TMSCl trimethylsilyl chloride
VEGF vascular endothelial growth factor
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